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Abstract Vesicular protein sorting-associated proteins (VPS,
including VPS11) are indispensable in the endocytic network,
in particular the endosome-lysosome biogenesis. Exome se-
quencing revealed the homozygous variant p.Leu387_
Gly395del in the VPS11 gene in two siblings. On immuno-
blotting, the mutant VPS11 protein showed a distinctly re-
duced immunostaining intensity. The children presented with
primary and severe developmental delay associated with myo-
clonic seizures, spastic tetraplegia, trunk and neck hypotonia,
blindness, hearing loss, and microcephaly. Neuro-imaging
showed severe hypomyelination affecting cerebral and cere-
bellar white matter and corpus callosum, in the absence of a
peripheral neuropathy. Electron microscopy of a skin biopsy
revealed clusters of membranous cytoplasmic bodies in der-
mal unmyelinated nerve axons, and numbers of vacuoles in
eccrine sweat glands, similar to what is seen in a classic lyso-
somal storage disease (LSD). Bone marrow cytology showed
a high number of storage macrophages with a micro-
vacuolated cytoplasm. Biochemically, changes in urinary
glycosphingolipids were reminiscent of those in prosaposin
deficiency (another LSD). The clinical and neuro-imaged fea-
tures in our patients were almost identical to those in some
recently reported patients with another variant in the VPS11
gene, p.Cys846Gly; underlining the presumed pathogenic po-
tential ofVPS11 defects. A new feature was the morphological
evidence for lysosomal storage in VPS11 deficiency: This
newly characterised disease can be viewed as belonging to
the complex field of LSD.
Introduction
Many gene defects lead to metabolic errors with correspond-
ing clinical symptoms already in early life. In child neurology,
the situation is well known that in a patient the neuro-devel-
opmental, neuro-imaged and other findings highly suggest the
presence of a neurometabolic disease, but classical biochem-
ical, genetic and other laboratory methods have failed to suf-
ficiently contribute to the exact diagnosis of such a progres-
sive disease. In such cases the recent facilities to screen high
proportions of the whole exome at once offer a realistic chance
(Sawyer et al 2016) to make a genetic diagnosis.
The VPS11 gene codes for the human homolog of the yeast
class C VPS11 protein; about 40 VPS proteins being known
for yeast (Kim et al 2001). VPS means Vacuolar (or Vesicle-
mediated) Protein Sorting, but the abbreviation is regularly
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used for the so-called vacuolar protein sorting-associated pro-
teins encoded by VPS genes. The mammalian homologs of
yeast class C VPS are remarkable for their association with
late endosomes and lysosomes (Kim et al 2001). The func-
tions of VPS are not fully understood, but some VPS seem to
be implicated in human diseases [for example, chronic apical
periodontitis, and genetically caused forms of Parkinson dis-
ease (Tang et al 2015)]. There is consent that VPS may be
involved in the trafficking of vesicle-enveloped molecules to
late endosomes and lysosomes. In this process, parts of the
endosomal and early lysosomal membranes seem to fuse
with each other; thereby controlling protein sorting and
other fundamental processes (Balderhaar and Ungermann
2013). The integration of VPS in the whole endosomal-
lysosomal, Bendocytic^ network, which requires a num-
ber of gene products in addition to VPS for its function
(Balderhaar and Ungermann 2013), was reviewed in
Edvardson et al (2015).
We report on the clinical, morphological, biochemical and
genetic findings in two siblings with severe hypomyelination
attributed to VPS11 deficiency (V11D). Recently, Edvardson
et al (2015) described a mutation in the VPS11 gene in a group
of hitherto undiagnosed patients characterised by a severe
neurodegenerative, in particular hypomyelinating disease.
Whole exome sequencing (Biskup 2010; Sawyer et al 2016)
in our patients revealed another VPS11mutation, thus provid-
ing the second observation of such a defect in humans. As
novel features in V11D, we describe distinct lysosomal stor-
age phenomena, and urinary lipid changes suggestive of lyso-
somal dysfunction. This shed some light on the possible
patho-mechanisms underlying the V11D condition, which
seems to represent a novel type of lysosomal storage disease
(LSD).
Clinical report
Patient 1 (Pat1, male) was born at 37 weeks of gestation to
healthy, consanguineous parents (cousins but with generation
skipping). Developmental delay was first recognised at the
age of 3 months. At the age of 6 months, fixation and follow-
ing with the eyes, which were initially acquired, was lost; the
boy had a pendular nystagmus and truncal hypotonia, and the
head circumference was below the 3rd percentile (P3).
Inspiratory stridor was noted. At the age of 12 months, weight
and length also were below P3. Opisthotonic posturing, limb
hypertonicity and fisting of the hands was reported, and head
control was markedly impaired. Liver, spleen and palpable
lymph nodes were not enlarged. During his stay at the hospi-
tal, short epileptic seizures of variable phenomenology were
recognised including sudden extension of the arms, upward
gaze of the eyes, myoclonic fits involving the face and shoul-
ders. Laboratory testing revealed slightly elevated liver
parameters, and mildly elevated serum lactate (3.8 mmol/l;
normal ≤ 2.44). At the age of 27 months, sensorineural hear-
ing loss was diagnosed and hearing aids introduced. At age
34 months, his inspiratory stridor depended on certain body
positions, feeding and swallowing had become difficult. He
showed simple communicative skills, responded to loud
speech and body contact by smiling and turning of the head.
Neurologic examination showed spastic tetraplegia with trunk
and neck hypotonia; the Babinski sign was positive.
Electroencephalograms with polymorphous changes and mul-
tifocal spikes had worsened compared to earlier exams. At the
age of 54 months, the mother reported on weakness and fa-
tigue, and long lasting common infections. The body mea-
sures were all distinctly below P3 but paralleled those of nor-
mal growth curves. Neurological examination unchangedly
showed the severe tetraspastic disorder with hyperactive ten-
don reflexes and positive Babinski signs, and almost no gross
motor function, and the blindness. Seizures were frequent with
twitching of the face and mouth, and jerks of one body half
especially when waking up. Occasionally, he experienced
grand-mal seizures. Electroencephalograms showed signs of
hypsarrhythmia when he was asleep, and multifocal activities
when awake. He showed luxation of the left hip, scoliosis and
thoracal kyphosis. At the age of 94 months, his seizures wors-
ened, he showed clusters of myoclonic seizures lasting up to
15 min which occurred immediately after waking up. He ap-
peared very weak and hypotonic. Electroencephalograms
displayedmultifocal sharp-waves and sharp-slow-waves com-
plexes. The size of the liver had increased on sonography
(11.3 cm, anterior axillar line) and was now at the upper limit
for age. The further course was characterised by almost total
immobility, seizures and recurrent lung infections, complica-
tions due to a gastro-oesophageal reflux disease and need of
gastrostomy. The patient died at 16 years of age.
Cerebrospinal fluid (CSF) findings including total protein
content were normal (at 12 months). Sensory and motor nerve
conduction velocities (NCV) were unremarkable (at 12, 73
and 94 months). Ophthalmological examination at the age
of 3 and 8 years revealed normal pupillar reactions, but poor
fixation and following of the eyes to lights. The fundi
displayed slightly granulated maculae without physiologic re-
flexes; the optic disks were distinctly pale, interpreted as atro-
phy of optic nerves corresponding to the observed visual loss.
MR imaging of the brain at the age of 12, 27 and 73 months
years revealed white matter signal changes indicative of
hypomyelination (high on T2w and iso- to slightly hyperin-
tense on T1w) of the entire supratentorial white matter, and
also the cerebellar white matter (Fig. 1). Inner and outer CSF
spaces were mildly enlarged though some progression could
be noted, and the corpus callosum got thin (less than 1 mm).
MR-spectroscopy of the occipital white matter at the age of
12months showed reducedN-acetylaspartate, but no evidence
for elevated lactate.
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Patient 2 (Pat2, female) was 5.5 years younger than her
brother (Pat1) and had a similarly severe disease. She de-
ceased at home already at the age of 16 months for unknown
reasons. The developmental delay and sequence of clinical
features were very similar to her brother’s first 16 months.
At the age of 3 months, the mother noted that the baby’s
movements were slow and sparse, she hardly turned her head
to look at the mother. At the age of 4.5 months, the child’s
developmental delay, muscle hypotonia, impaired spontane-
ous moving and inability to fix with the eyes were document-
ed for the first time. At age 6 months, she had a severe devel-
opmental delay with general hypotonia, and almost no
spontaneous movements. A spastic movement disorder was
suspected, and she exhibited an inspiratory stridor. At the age
of 9 months, the mother reported on opisthotonic posturing
and little motor activities. At examination, the stridor was
marked. She had also cushion-like dorsal swellings on hands
and feet, and showed a uvula bipartita. She showed truncal
hypotonia and hypertonicity of the extremities, her head con-
trol was poor and she showed little movements. Tendon re-
flexes and Babinski sign were absent. She did not react to light
nor followed with the eyes. Electroencephalograms displayed
multifocal sharp and spike waves. NCV measuring was nor-
mal. Laboratory tests revealed mildly elevated serum lactate
and carnitine. Transaminases were at the upper limit of nor-
mal, and lactatdehydrogenase distinctly high. On palpation,
the liver was 2 cm below the ribs, but, sonographically, the
organ was unremarkable. The ophthalmologist found pale op-
tic disks indicating atrophic optic nerves. The child was con-
sidered essentially blind. On three attempts, cerebral MR im-
aging could not be performed because of respiratory and cir-
culatory problems.
Materials and methods
DNA samplesGenomic DNAwas isolated from fibroblasts of
the two patients and from blood samples of the parents using
the QIAamp DNA Mini Kit (no. 51306, Qiagen NV, Hilden,
Germany) following the manufacturer’s instructions.
Urinary lipid samples The 24 h-urines were collected,
homogenised by shaking, divided into 10 ml portions and im-
mediately frozen at −20 °C. Thawed portions were immediately
lipid-extracted by three subsequent phase partitions of chloro-
form/methanol/urine or /water mixtures, and the final organic
phase was the lipid extract to be used (details on request).
Concentrated extracts corresponding to about 10–15 ml urine,
and an earlier prepared sulfatide lipid standard (3 to 5 μg) were
used for two-dimensional thin-layer chromatography (TLC) on
20 × 20 cm silicagel TLC plates (no. 1.05721, Merck,
Darmstadt, Germany) as described (Schlote et al 1991; Paton
et al 1992; Kuchař et al 2009). The anisaldehyde/sulfuric lipid
staining reagent was used as described (Paton et al 1992). A
semi-quantitative method for the determinaton of single
glycosphingolipids is described in the Supplementary materials
available to this article.
Exome analysis The exomes of patient 2 and her parents were
sequenced using the following protocol: DNA was enriched
using the SureSelectXT V5 exome kit (Agilent, Boeblingen,
Germany) according to the manufacturer’s instructions.
Sequencing was performed on a HiSeq 2500 sequencer
(Illumina, San Diego, CA, USA). On average, 217 million
paired reads with a length of 100 bp were produced per exome
Fig. 1 MR imaging of the brain in patient 1 at the age of 12 (a,b), 27
(c,d) and 73 months (e,f). Axial images at the level of the basal ganglia
(a,c,e) as well as the cerebellum (b,d,f) show signal changes which
indicate hypomyelination: there is high signal on the proton density (a)
and T2w (c,e) images of the supratentorial white matter. Inner and outer
CSF spaces were mildly enlarged on follow-up and corpus callosum got
thin (black arrow in e) corresponding to atrophy. The cerebellum was not
specifically affected by atrophy, but cerebellar white matter was also
hypomyelinated, best seen at age 12 months (b), white arrow
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(220, 220, and 210 million for the index and the two parents,
respectively). Reads were demultiplexed with Casava (1.8.2;
Illumina) and adapter sequences removed with Skewer
(0.1.116). Trimmed reads were mapped with BWA [0.7.2.
(Li and Durbin 2009)] using the mem algorithm against the
human reference genome (hg19 from UCSC). This yielded an
average coverage of 167 for the enriched target regions (117,
198 and 187 for the index and the two parents, respectively).
Variant calling, including small insertions and deletions as
well as single nucleotide variants (SNVs), was performed
using VarScan 2.3 and samtools mpileup 0.1.18 with bcftools
(0.1.17) and vcfutils.pl. Calls also found in dbSNP (Database
of Single-Nucleotide Polymorphisms, Bethesda, MD, USA),
National Library of Medicine (Build ID: 138; http://www.
ncbi.nlm.nih.gov/SNP/) or the Exome Variant Server
database (NHLBI GO Exome Sequencing Project [ESP],
Seattle, WA, USA; http://evs.gs.washington.edu/EVS/) with
an allele frequency >5 % were removed. In addition,
frequently observed variants in an in-house database produced
from the same sequencing technology and enrichment kit
were removed (>80 %, minimum number of references: 21).
Transcript and protein alterations (functional consequences)
were annotated with in-house software (unpublished) using a
proprietary transcript database based on ENSEMBL (v75),
RefSeq (as mapped in UCSC on 2014-11-06), and CCDS
(release 15). Only variants potentially changing the protein
sequence were used for further analysis; intronic, UTR and
synonymous mutations were removed. Finally, the variant list
was filtered for all variants occurring in both affected family
members using a self-developed tool (unpublished). A trio
analysis was conducted to further filter the variant list. The
remaining SNVs and INDELs of the index patient were used
to check if, (i) the index patient is compound heterozygous
and each parent carries one heterozygous mutation, (ii) index
patient has a homozygous mutation and parents are heterozy-
gous, and, (iii) index patient has a de-novo mutation. All three
cases were automatically computed by a self-developed tool
(unpublished). Sanger sequencing for VPS11 analysis of pa-
tient 1 and validation of NGS results was carried out using
standard PCR-based techniques and BigDye (Life
Technologies GmbH, Darmstadt, Germany) chemistry
(primers available on request).
Immunoblot preparation Fibroblasts were lysed in PBS/
1 % Triton X-100 and centrifuged for supernatants.
Lysates with 30 μg protein were separated using sodium
dodecyl sulfate polyacrylamide gel electrophoresis (8 %
polyacrylamide; protein ladder NEB P7711) and transferred
to PVDF transfer membranes (no. IPVH00010, Immobilon-
P Millipore, Merck, Darmstadt, Germany). These mem-
branes were then probed with antibodies overnight at 4 °C
against VPS11 (no. 19140-1-AP, Proteintech, Manchester,
U.K.), Jak2 (no. 3229, Cell Signaling, Bio-Rad, München,
Germany) and tubulin (no. ab6160, Abcam, Cambridge,
U.K.), respectively, washed in TBS and incubated for 1 h
with secondary antibodies conjugated with peroxidase (no.
7074, Cell Signaling, and no. 6845-1, Abcam, respective-
ly). The membranes were developed using Amersham ECL-
Prime Western Blotting Detection Reagent (no. RPN2232,
GE Healthcare, Merck) according to the manufacturers in-
structions and exposed to an X-ray film. Quantitation was
performed using a densitometer.
Results and discussion
The VPS11 mutation in relation to the clinical picture
While preparing the description of these patients with the new
defect in the VPS11 gene, the publication by Edvardson et al
(2015) appeared that described eight patients in four
Ashkenazi-Jewish families with a defect in the VPS11 gene
identified as p.Cys846Gly. The VPS11 variant in our patients,
p.Leu387_Gly395del (c.1158_1184del, NM_021729.5)
(Fig. 2), is a hitherto unknown in frame deletion of nine amino
acids in a highly conserved region of the VPS11 gene (deletion
not observed in public databases). The deletion variant was
homozygous in our patients and heterozygous in both parents.
In Fig. 2, the wild type sequence scales at the top (Sanger
sequencing) and the bottom (NGS) are not congruent for the
reasons given in the figure legend. In Fig. 2, lane b, only one
of the heterozygous sequences is identified by the wild type
scale at the top. The other sequence is shifted due to the dele-
tion (peak colours/identities deviating from the wild type se-
quence in a). Interestingly, the clinical picture described in the
patients bearing the p.Cys846Gly was very similar to that
observed in our patients. The ‘appendicular spasticity’
(Edvardson et al 2015) which means the spastic peripheral
limb muscles as a hypertonic system appending to the hypo-
tonic system of the remaining body, essentially the trunk, was
a leading symptom shared with our patients. Moreover, the
acquired microcephaly, seizure manifestations and severe
hypomyelination affecting cerebral and cerebellar white mat-
ter with thinning of the corpus callosum (Fig. 1), were also
convincingly shared. This clinical similarity of the described
(Jewish) patients (Edvardson et al 2015) and our (non-Jewish,
Turkish) patients suggested that the VPS11 defects were
causative for the disease, in accordance to the absence of
any other reported severe defect in the whole exome anal-
yses. Our second observation of a VPS11 defect has now
strongly supported the pathogenic impact of such a defect,
which was anticipated by Edvardson et al (2015). The dif-
ferent mutations in the same gene leading to the same dis-
ease in both observations reflect a typical situation in many
genetic disorders.
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The protein phenotype in VPS11 deficiency
The immunoblot shown in Fig. 3 compares the mutated pro-
tein in our patients to that in normal controls. Patients 1 and 2
have less intensely immunostained VPS 11 bands as com-
pared to the controls. Normalisation of the staining intensities
on the basis of reference proteins revealed the distinct differ-
ences given in the legend to Fig. 3. However, the distinct
reduction of the amount of the mutant VPS11 cannot, yet, be
explained. A deletion-mediated instability of the transcript, or
a rapid decay of the mutant VPS11 protein initiated by the
cellular control systems might have been responsible.
Although in Fig. 3 the mutant VPS11 bands apparently had
slightly faster migration rates as compared to the controls, this
difference may be questioned because the Jak2 standard in the
patient 2 lane behaved similarly (by an artifact due to the
overloaded Jak2 band?). However, in the patient 1 lane, the
Jak2 standard did obviously not behave atypically. So, the
migration rate of the mutant VPS11 might still have been
slightly increased due to the reduction in size, as compared
to normal VPS11, by the described nine amino acid-deletion.
The lysosomal involvement in VPS11 deficiency
Some contribution to possible disease patho-mechanisms in our
patients came from Bnature experiments^. The natural course of
their disease resulted in a highly pathologic involvement of the
lysosomal compartments in different cell types. The morpho-
logic changes (Figs. 4 and 5) left no doubt that a leading aspect
of the disease (now called VPS11 deficiency [V11D]) was that
of a lysosomal storage disease (LSD). The storagemacrophages
seen in the bone marrow smear from patient 1 (Fig. 4)
resembled the storage cells in infantile sphingomyelinase defi-
ciency (Niemann-Pick disease type A), although, in contrast to
the Niemann-Pick A cells, they seemed to be mechanically
instable, as could be concluded from the occurrence of high
numbers of cell debris with the appearance of irregular clusters
of storage vacuoles unrelated to any cell nuclei. Unexplained
were the very distinct, condensed nucleoli in the storage cell
nuclei (Fig. 4; part a, lower green encircled nucleus; part b,
green encircled nucleus). Electron microscopy of the skin biop-
sies of both patients revealed numbers of lysosome-equivalent
Control 1 Control 2Patient 2 Patient 1
Fig. 3 Immunoblots of normal and VPS11-mutated fibroblast extracts
(each with 30 μg protein). It is seen that in patients 1 and 2 the VPS11
bands have reduced immunostaining intensities as compared to the two
normal controls. Normalisation of the quantified VPS11 stain intensities
on the basis of the Jak2 (5 μg per band) intensities revealed for the VPS11/
Jak2 ratios, 0.26 and 0.31 in patient 2 and 1, respectively, as compared to
1.63 and 1.58 in the controls. Similar normalisation for the VPS11/tubulin
(5 μg) ratios revealed 0.2 and 0.134 in patient 2 and 1, respectively, as
compared to 0.72 and 0.47 in the controls. For a possibly slightly enhanced
migration rate of the mutant VPS11, see BResults and discussion^
Fig. 2 Sequencing data of the
VPS11 mutation, i.e. the deletion
given as the yellow area in c or, in
d and e, the horizontal black lines.
Shown are Sanger sequences of a
wild type, b mother
(heterozygous), c patient 2
(homozygous), and reads
obtained from the exome next
generation sequencing from d
mother (heterozygous) and e
patient 2 (homozygous). The
apparent shift in position of the
deletion in Sanger vs. NGS
sequencing reads is due to the
identical ATGG characterising in
wild type both sides of the region
that is deleted in b to e. The
calling algorithm used the most 5′
position in contrast to the HGVS
nomenclature in which the most
3′ position is recommended
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clear vacuoles in the eccrine sweat glands (Fig. 5a), but also
areas with mostly dense, multiform membranous cytoplasmic
bodies (Fig. 5b,c) located to unmyelinated axons, as well as less
dense bodies in fibrocyte processes (Fig. 5d). The structures in
Fig. 5b,c were identical to the structures shown, e.g., in the LSD
type known as sialidosis (Martin et al 1981). Figure 5a and b
belonged to patient 1, Fig. 5c and d to patient 2; the depicted
ultrastructures were identical. The frequency and intensity of
these ultrastructural storage phenomena were much higher in
patient 1 (skin biopsy taken at age 73 months) than in patient 2
(biopsy at 7 months). This aspect of lysosomal involvement in
V11D was not reported to be characteristic for the patients
investigated by Edvardson et al (2015), although the authors
spoke of mild accumulation of cargo in the late endosome. The
Fig. 5 Electron microscopy of
skin biopsies from the present
patients. Horizontal bars mark
1 μm in each graph. a, eccrine
sweat gland in patient 1 (EN,
nuclei of gland epithelia); note the
numberless, almost clear vacuoles
representing storage lysosomes.
b, large round area in the mid:
unmyelinated nerve ending axon
filled with sometimes dark,
polymorphous membranous
cytoplasmic bodies representing
lipid and other materials storing
lysosomes, in patient 1. c, this
finding in patient 2 is identical to
that shown in b. d, also from
patient 2, shows in the mid a
process of a fibrocyte containing
storage bodies similar to those
seen in b and c (MN, normally
myelinated dermal nerve fibres)
a edcb
Fig. 4 Bone marrow cytology in present patient 1 (male). Pathologic
cells encircled in yellow. Horizontal blue bars in graphs mark 20 μm.
Parts a to e, storage macrophages filled with granules which on direct
microscopy mostly appear as micro-vesicles. The reddish nuclei in parts a
and b are encircled in green, and two of them display distinct dark
nucleoli. In parts c and d, the nuclei are hidden by engulfed or overlaid
leukocytic cells. In part e, a relative large reddish nucleus encircled in
green is loosely associated with a granular and micro-vacuolar mass
which does not seem to be coated by a cell membrane (disintegrating
storage macrophage?)
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late endosome is close to the lysosome and accumulates
substances in some LSD. The apparent difference in
lysosomal involvement between the observation by
Edvardson et al (2015) and ours could be due to the different
nature of the VSP11 mutations in both: p.Cys846Gly and
p.Leu387_Gly395del affect very different though conserved
regions of the gene. The different mutational changes in the
VPS11 proteins may trigger different tissue phenotypes, while
they lead to almost identical clinical phenotypes of the disease.
Whether the lysosomal involvement shown in Figs. 4 and 5 in
fact is an expression also of the pathogenic mechanisms which
lead to the patients’ brain disease, is unclear. However, by anal-
ogy to many known LSD, such an interpretation seems to be
admissible. If correct, this interpretation should predict that the
patients described by Edvardson et al (2015), when studied in
the same way as our patients, would show a similar lysosomal
involvement which, only in quantitative terms, might be less
distinct than in our patients.
A biochemical abnormality in VPS11 deficiency
Some types of glycosphingolipids are known to have elevated
urinary levels in lysosomal lipidoses such as metachromatic
leukodystrophy, Fabry disease and prosaposin deficiency
(Kuchař et al 2009). Patient 1 was remarkable for the com-
bined elevations of monohexosylceramides, sulfatides,
tetrahexosylceramides and other glycosphingolipids in two
independent urine samples as compared to an age-matched
control (Fig. 6). In the figure, the corresponding lipid spots
seen on two-dimensional thin layer chromatograms were in-
creased in their staining intensity as compared to the shown
control chromatogram. The glycolipid pattern had some sim-
ilarity to the pattern seen in prosaposin deficiency which is a
severe lysosomal lipidosis (Paton et al 1992; Kuchař et al
2009). The lipid analyses were performed 20 years ago.
Patient 1 died a decade ago, and no urinary samples had been
preserved for a confirmatory mass spectrometric analysis.
However, we had some experience with the identification of
glycosphingolipids and the differentiation of normal and lyso-
somal defect-associated, elevated levels on thin-layer chro-
matograms (Paton et al 1992). The different fundamental
and methodological caveats of this type of urinary lipid anal-
ysis as well as a semi-quantitative method for the lipid deter-
mination on the present chromatograms are described in the
Supplementary materials available to this article. We conclud-
ed that the shown urinary glycosphingolipid abnormality in
patient 1 is a marker of the lysosomal involvement in V11D.
The hypomyelination in VPS11 deficiency
A distinct clinical feature of our patients as well as those
described by Edvardson et al (2015) is hypomyelination,
allowing to include V11D within hypomyelinating diseases
(HMD). HMD comprise a group characterised by a perma-
nent, substantial deficit in myelin deposition in the brain
(Barkovich 2015). They are genetically but also clinically het-
erogeneous. The gene defects were proposed to trigger im-
paired functions of the oligodendrocyte and its cellular pre-
cursors (Pouwels et al 2014). Some LSD such as infantile
GM1 and GM2 gangliosidosis, Salla disease and fucosidosis
were shown to have neuro-imaging characteristics of HMD,
allowing to include them also within HMD (Steenweg et al
Fig. 6 Urinary lipids in two independent samples from patient 1, and a
selected normal control (see Supplementary materials available to this
article). On the stained, two-dimensional thin-layer chromatograms, the
following glycosphingolipid groups were identified: 1, GM3 ganglioside;
2, tetrahexosylceramides; 3, trihexosylceramides; 4, sulfatides; 5,
dihexosylceramides; 6, monohexosylceramides. Morover, some
phospholipids were identified and given the symbol P or, in the case of
sphingomyelin, SM. The ? denotes unidentified compounds. SU is the start
point for the urinary total lipid extract and SS that for the external standard
(sulfatides, 3 to 5 μg); SE is this standard which ran slightly higher than the
patients spots no. 4 due to its different fatty-acid composition. Note the
more intensely stained spots no. 6, 4 and 2 and additional 6 and 2 spots in
Patient 1 as compared to Control, viewed as specific glycosphingolipid
elevations in the patient. For spots no. 1, see Supplementary materials, in
which also a semi-quantitative evaluation of the spot staining intensities as
measures of lipid concentrations is described
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2010). Some clinical features in our V11D patients, for exam-
ple, nystagmus and inspiratory stridor (attributed to the pha-
ryngeal and tongue slackness), were shared with classical
HMD, in particular Pelizaeus-Merzbacher disease (PMD).
Disease courses with the absence of almost any developmen-
tal progress and without a predominant seizure disorder, how-
ever, are rare in classical PMD or other genetically defined
HMD. The manifestation of some classical LSD, though only
in their early onset forms with a severe clinical course, as
HMD (Steenweg et al 2010), might suggest that also in
V11D lysosomal dysfunctions trigger the hypomyelination.
However, the lysosomal affection in V11D might be different
from that in classical LSD.
For the new disease, V11D, it can be expected that studies
of V11D cells in vitro will provide us with interesting data on
the normal and defective lysosome biogenesis, and give in-
sight into the functions of VPS11.
Conclusions
The role of VPS11 in the complex endosomal-lysosomal path-
ways might explain that the V11D condition has several phe-
notypic aspects of a LSD. The morphological evidence for
lysosomal storage in V11D came, at the ultrastructural level,
from high numbers of membranous cytoplasmic bodies in der-
mal unmyelinated axons and groups of vacuoles in eccrine
sweat glands, and, at the bone marrow cytological level, from
a high number of storage macrophages with a foamy cyto-
plasm. So, classical morphologic approaches should remain
additional diagnostic options, as neuro-pathologic findings in
biopsies may suggest new disease aspects which might not
directly become obvious from the unravelled genotype. In ad-
dition to the morphologic evidence, a biochemical marker of a
lysosomal dysfunction in the present V11D patients was sug-
gested to exist by the observed urinary glycosphingolipid ab-
normality resembling the changes in prosaposin deficiency.
The defective endo-lysosomal molecule trafficking in V11D
might have the consequence that different proteins (for exam-
ple, prosaposin) destined to function in the mature lysosome
could not reach this compartment, leading to a scenario well
comparable to that in many LSD with primary defects of lyso-
somal proteins. According to the novel findings, V11D can be
viewed as belonging to LSD which today include many types
in which the metabolic bases are very different from the old
principle of a deficient lysosomal enzyme leading to lysosomal
storage. In accordance with the substantial hypomyelination
known for some severe, early-onset forms of classical LSD,
and in some correspondence to the here described V11D dis-
ease, lysosomal storage processes can be viewed as some of the
candidates for the largely puzzling pathogenic factors in HMD.
CSF cerebrospinal fluid, HMD hypomyelinating disease,
LSD lysosomal storage disease, MR magnetic resonance,
NCV nerve conduction velocity, NGS next generation se-
quencing, P3 3rd percentile, PMD Pelizaeus-Merzbacher dis-
ease, TLC thin layer chromatography, T2w T2-weighted im-
age, V11D VPS11 deficiency
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